Featured Publications
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerDose-limiting organPositron emission tomographyBreast cancerMSv/MBqOptimal imaging timeHuman radiation dosimetryPET/CT imagesOrgan time activity curvesGreater tumorTime-activity curvesPurposeThe purposeHuman dosimetryEmission tomographyBiodistribution dataEffective dosePatientsAdverse effectsCancerLiverImaging parametersWomenPresent studyTomographyDays
2022
PET Imaging in Animal Models of Alzheimer’s Disease
Chen B, Marquez-Nostra B, Belitzky E, Toyonaga T, Tong J, Huang Y, Cai Z. PET Imaging in Animal Models of Alzheimer’s Disease. Frontiers In Neuroscience 2022, 16: 872509. PMID: 35685772, PMCID: PMC9171374, DOI: 10.3389/fnins.2022.872509.Peer-Reviewed Original ResearchAnimal modelsPreclinical PET imagingPET imagingOngoing clinical trialsΒ-amyloid plaquesAnimal model developmentPathogenesis/progressionTau-PETClinical trialsTau tanglesTherapeutic effectAD modelNovel treatmentsAlzheimer's diseaseDrug action mechanismsDiseaseAction mechanismImagingPatientsPETPlaquesProgressionTrialsAntemortem
2021
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers In Pharmacology 2021, 12: 627693. PMID: 33986665, PMCID: PMC8111013, DOI: 10.3389/fphar.2021.627693.Peer-Reviewed Original ResearchDifferent molecular subtypesBreast cancerPositron emission tomographyMolecular subtypesEmission tomographySingle photon emission tomographyBreast cancer patientsResponse of therapyBreast cancer therapyNew therapeutic agentsPreclinical advancesMolecular imaging methodsCancer patientsCare treatmentCommon cancerPreclinical studiesTherapeutic strategiesCancerDrug resistanceTherapeutic agentsTherapyNew targetsCancer therapyPrecision medicinePatients
2019
Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesMaytansineMiceMice, NudePositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2TrastuzumabTreatment OutcomeTumor BurdenXenograft Model Antitumor AssaysX-Ray MicrotomographyZirconiumConceptsT-DM1 therapyBreast cancerTumor volumeHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2BT-474 tumorsGrowth factor receptor 2HER2-positive tumorsFactor receptor 2HER2 expressionBCa patientsReceptor 2TherapyTumorsEarly responseBetter delineationPertuzumabPoor delineationMBq/MiceTreatmentResponsePatientsHER2
2018
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Molecular Imaging 2018, 17: 1536012117745386. PMID: 29357745, PMCID: PMC5784567, DOI: 10.1177/1536012117745386.BooksConceptsHuman epidermal growth factor 2HER2 expressionHER2 statusEpidermal growth factor 2Treatment of patientsHER2-positive cancersWhole-body assessmentStandard diagnostic techniquesMetastatic settingGrowth factor 2Breast cancerClinical studiesNuclear medicineTumor fociInvasive biopsyAlternative treatmentTime of analysisSmall sample sizeTherapyNuclear imagingBiopsyPatientsFactor 2TumorsCancer